Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BALCHEM CORPBCPC · Entity 3839 | SVP and Chief R&D Officer | February 11, 2026 | February 13, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BALCHEM CORP
Report date February 11, 2026 · Filed February 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 3,200 |
Reported balance
After 2026-02-11 transaction · row 1
1 source rowRow 1 · 2026-02-11 · Grant · Acquired 700 · Balance 3,200 F1: Ownership of restricted stock vests in Reporting Person over a 3-year period (25% on the first anniversary of the grant date, 25% on the second anniversary of the grant date, and 50% on the third anniversary of the grant date), subject to restrictions on transfer in accordance with the provisions of a Restricted Stock Grant Agreement between the Issuer and the Reporting Person. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $178.68 · Expires 2036-02-11 | Direct | 2,600 |
Reported balance
After 2026-02-11 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-02-11 · Grant · Acquired 2,600 · Balance 2,600 F2: Options vest 20% Year 1, 40% Year 2, and 40% Year 3. |
| Common StockSEC Table I · non-derivative | Indirect401(k) Plan | 20 |
Reported balance
Holding disclosure · report date 2026-02-11 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 20 |
Filing footnotes · ownership attribution and instrument terms
F1: Ownership of restricted stock vests in Reporting Person over a 3-year period (25% on the first anniversary of the grant date, 25% on the second anniversary of the grant date, and 50% on the third anniversary of the grant date), subject to restrictions on transfer in accordance with the provisions of a Restricted Stock Grant Agreement between the Issuer and the Reporting Person.
F2: Options vest 20% Year 1, 40% Year 2, and 40% Year 3.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 11, 2026 Filed Feb 13, 2026 23:40 UTC | BALCHEM CORP BCPC · Entity 3839 | GrantStock Option · Derivative | 2,600 | $0.00 Strike: $178.68 | $0.00 |
DisclosureSEC source: 0001140361-26-005533 · form4.xml · derivative · entry 3 Graham George · CIK 0002082308 · SVP and Chief R&D Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,600 Underlying: Common Stock · 2,600 shares Expires 2036-02-11 F2 · derivative.exercise_date: Options vest 20% Year 1, 40% Year 2, and 40% Year 3. Read SEC document |
| February 11, 2026 Filed Feb 13, 2026 23:40 UTC | BALCHEM CORP BCPC · Entity 3839 | GrantCommon Stock | 700 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-26-005533 · form4.xml · nonDerivative · entry 1 Graham George · CIK 0002082308 · SVP and Chief R&D Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,200 F1 · shares: Ownership of restricted stock vests in Reporting Person over a 3-year period (25% on the first anniversary of the grant date, 25% on the second anniversary of the grant date, and 50% on the third anniversary of the grant date), subject to restrictions on transfer in accordance with the provisions of a Restricted Stock Grant Agreement between the Issuer and the Reporting Person. Read SEC document |
| October 20, 2025 Filed Oct 22, 2025 20:50 UTC | BALCHEM CORP BCPC · Entity 3839 | GrantCommon Stock | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-25-038951 · form4.xml · nonDerivative · entry 1 Graham George · CIK 0002082308 · SVP and Chief R&D Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,500 F1 · shares: Ownership of restricted stock vests in Reporting Person ratably over a 3 year period (25% on the first anniversary of the grant date, 25% on the second anniversary of the grant date, and 50% on the third anniversary of the grant date), subject to restrictions on transfer in accordance with the provisions of a Restricted Stock Grant Agreement between the Issuer and the Reporting Person. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.